News
Can-Fite's Namodenoson Featured in Biomedicines for Liver Cancer and MASH Treatment Insights
15 Apr 24
News
Can-Fite BioPharma Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
3 Apr 24
Government, News, Regulations
Can Fite Biofarma: Q4 Earnings Insights
28 Mar 24
Earnings
Can Fite Biofarma FY GAAP EPS $(0.01), Same YoY, Sales $743.00K Down From $810.00K YoY
28 Mar 24
Earnings, News
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
30 Jan 24
Government, News, Regulations
Press releases
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
15 Apr 24
Press Releases
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
3 Apr 24
Press Releases
Can-Fite Reports 2023 Financial Results and Clinical Update
28 Mar 24
Press Releases
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
11 Mar 24
Press Releases
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
28 Feb 24
Press Releases
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
30 Jan 24
Press Releases